For the 350 million people chronically infected with HBV, the two therapeutic approaches currently available are immunomodulatory agents and antiviral chemotherapy. The first therapeutic agent was interferon-alpha (IFN-alpha), whose dual mode of action includes both antiviral and immunomodulatory effects. Unfortunately, extended IFN-alpha treatment is effective in no more than 15-25% of patients, and is associated with a wide spectrum of adverse reactions, although these limitations will be partially obviated by the likely approval of peginterferon-alpha for use in chronic HBV in the near future.
It is the nucleoside analogue named lamivudine that has become the gold standard worldwide for use in patients with chronic hepatitis B. Nevertheless, lamivudine-induced decreases in viral load are difficult to sustain over time due to occurrence of viral drug resistance. The drug resistance is associated with mutations in the very conserved catalytic polymerase /reverse transcriptase domain of the gene located at the YMDD motif.
The recent arrival of nucleotide analogue of HBV therapy is adefovir dipivoxil, whose antiviral efficacy was confirmed in large-scale clinical trials in both HBeAg-positive and HBeAg-negative chronic hepatitis B patients, achieving more than a 3-log decrease in viral load, drop in serum ALT levels, and improvement in liver histology after one to two years of treatment. Although virus resistant mutants did not seem to occur in adefovir-treated patients in 48 weeks and then up to 60 weeks of treatment, this did not turn out to be the case upon treatment after 96 weeks. The newly discovered mutant to adefovir (rtN236T) is located downstream from the YMDD motif in the D domain of the viral polymerase.
Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn
Foods of the future
15.08.2018 | Georg-August-Universität Göttingen
New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference
Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
17.08.2018 | Event News
08.08.2018 | Event News
27.07.2018 | Event News
17.08.2018 | Physics and Astronomy
17.08.2018 | Information Technology
17.08.2018 | Life Sciences